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Abstract 
Electroanalytical methods based on square-wave adsorptive-stripping voltammetry (SWAdSV) and flow-injection analysis with SWAdSV detec- 
tion (FIA-SWAdSV) were developed for the determination of paroxetine (PRX). The methods were based on the reduction of PRX at a mercury 
drop electrode at −1.55 V versus Ag/AgCl, in a borate buffer of pH 8.8, and the possibility of accumulating the compound at the electrode surface. 
Because the presence of dissolved oxygen did not interfere significantly with the analysis, it was also possible to determine PRX using FIA- 
SWAdSV. This method enables analysis of up to 120 samples per hour at reduced costs. Both methods developed were validated and successfully 
applied to the quantification of PRX in pharmaceutical products. 
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1. Introduction 
 
Paroxetine (PRX, Fig. 1), a selective serotonin reuptake 
inhibitor (SSRI), has been approved by the US Food  and 
Drug Administration as safe and effective in the treatment of 
depression, generalized anxiety disorder, social anxiety disorder, 
panic disorder, obsessive compulsive disorder and posttraumatic 
stress disorder. Since its introduction to the market in 1991 
a large number of analytical methodologies for PRX deter- 
mination have been published. Because of the ever-increasing 
need for analytical methods with high sample-throughput, low 
limits of detection, and low maintenance costs, new method- 
ologies are constantly being developed. During the past 6 
years the majority of these methods were based on chro- 
matography; high-performance liquid chromatography coupled 
with ultraviolet/diode array [1–11], mass [12–18], fluorimetric 
[19,20], and coulometric [21] detectors; gas chromatography 
with mass [22–24], flame-ionisation [25], nitrogen–phosphorus 
[26] and electron-capture [27] detection; micellar electroki- 
netic capillary chromatography [28]; and thin layer chro- 
matography  [9,29].  Capillary  electrophoresis  [30–32], flow- 
 
 
 
injection analysis with ultraviolet detection [33], and visible 
spectrophotometry [34,35] have also been applied in the analysis 
of PRX. 
Although the electrochemical determination of the other 
SSRIs, fluoxetine [36], fluvoxamine [37,38], sertraline [39,40], 
and citalopram [41] by square-wave adsorptive-stripping 
(SWAdSV) has been described, only one electrochemical study 
of PRX, based on oxidation, has been published to date [6]. 
Adsorptive stripping voltammetry is a highly sensitive and 
selective technique for the analysis of organic compounds which 
can be accumulated at the hanging mercury drop electrode 
(HMDE) surface and afterwards stripped off by applying a 
potential scan [42]. This allows their selective pre-concentration 
at the electrode; a high sensitivity is also obtained, due to the use 
of a high frequency square-wave potential scan in the reduction 
step [43,44]. Furthermore, this type of potential scan decreases 
the interference of dissolved oxygen, enabling the inclusion of 
the HMDE in a flow-injection system without prior or on-line 
oxygen removal [45]. The previous concepts were used in the 
development of a SWAdSV method for PRX analysis under 
batch conditions. Furthermore, a flow-injection analysis method 
with SWAdSV detection (FIA-SWAdSV) was developed for the 
same purpose. The methods of analysis were optimised, val- 
idated, and successfully applied to quantification of PRX in 
pharmaceutical products. 
 
  
 
 
Fig. 1.  Chemical structure of PRX. 
 
2. Experimental 
 
2.1. Apparatus 
 
Voltammetric measurements using SWV and SWAdSV were 
performed with a Autolab PGSTAT12 potentiostat (Metrohm- 
EcoChemie), controlled by a PC by use of GPES 4.9 software 
from Metrohm-EcoChemie, and a Metrohm 663 VA stand con- 
taining a three-electrode cell (all Metrohm). This voltammetric 
cell consisted of a multimode mercury working electrode, used 
in the static mercury-drop position (SMDE), an Ag/AgCl/KCl 
3 mol L−1 reference electrode, and a glassy-carbon auxiliary 
electrode. This system was used both under batch conditions 
and as the detector in the developed single-manifold FIA sys- 
tem. 
In the FIA system, the solutions were transported to the 
voltammetric detection cell by a Gilson Minipuls 3 peristaltic 
pump, using PTFE tubing (i.d. 0.8 mm). Samples and standards 
(Vinj = 500 µ,L) were introduced into the carrier stream through 
a six-port Rheodyne type 5041 injection valve. 
In the voltammetric flow cell used [45] the glass capillary of 
the SMDE is inserted into a PTFE adapter head and the  flow 
is directed towards the mercury drop. This adapter head [46] 
enables reproducible repositioning of the glass capillary when- 
ever the flow cell is dismounted and then remounted. The adapter 
head, the reference electrode, and the counter electrode are con- 
tained in a glass cell, which is filled with the solution used as 
the carrier stream. A drain ensures a constant level of solution 
to be maintained during the work. 
 
2.2. Reagents 
 
A PRX hydrochloride hemihydrate standard was provided 
by GlaxoSmithKline (Stevenage, Herts, UK) and used with- 
out further purification. Stock solutions of PRX were prepared 
by dissolution of precisely weighed amounts of the standard 
in water.  These stock solutions were diluted with    electrolyte 
solution to furnish the desired concentration for analysis. All 
other reagents, of p.a. quality, were purchased from Merck and 
Sigma–Aldrich. All solutions were prepared using deionised 
water (conductivity <0.1 µ,S cm−1). 
For optimisation of electrolyte pH several universal buffers 
(I = 0.3 mol L−1) [47] between pH 1.9 and 11.6 were used. After 
optimisation a pH 8.8 borate buffer (0.2 mol L−1) was used in 
both the SWAdSV method and the FIA-SWAdSV method. 
 
2.3. Procedures 
 
2.3.1. General procedure 
To obtain the background voltammogram by use of SWAdSV 
a 10.00-mL volume of the supporting electrolyte was introduced 
in a voltammetric cell and purged with oxygen-free nitrogen 
for 300 s. The required accumulation potential (Eacc) was then 
applied to the electrode for a selected accumulation time (tacc) 
while the solution was stirred. Finally, stirring was stopped 
and a square-wave voltammogram was recorded by   applying 
a potential scan in the negative direction. After recording the 
background voltammogram, an aliquot of the analyte (standard 
or sample) solution was added and the procedure was repeated 
using a purge time of 10 s. 
Background voltammograms using FIA-SWAdSV were 
obtained by simply applying, after the selected accumulation 
period, a square-wave potential scan in the negative direction 
while the electrolyte flowed through the adapter head. 
 
2.3.2. Validation procedure 
The linear range, limit of detection (LOD), limit of quan- 
tification (LOQ), repeatability, intermediate precision, recovery 
and selectivity were evaluated [48]. 
The linear range was determined by analysing PRX solu- 
tions in the ranges 1.00 × 10−7  to 3.90 × 10−6 mol L−1    and 
3.00 × 10−6 to 2.10 × 10−5 mol L−1 for the SWAdSV and FIA- 
SWAdSV methods, respectively. The LOD and LOQ were cal- 
culated from the linear calibration curve [49]. 
Repeatability  and  intermediate  precision  were  assessed 
at   three   concentrations.   For   the   SWAdSV   method  con- 
centration     levels     of     6.00 × 10−7,     1.50 × 10−6,   and 
2.40 × 10−6 mol L−1 (tacc 10 s) and 2.00 × 10−7, 5.00 × 10−7, 
and 8.00 × 10−7 mol L−1 (tacc 30 s) were used. The precision of 
the flow-injection method was evaluated by use of 4.50 × 10−6, 
9.00 × 10−6,  and  1.35 × 10−5 mol L−1    PRX  solutions.  To 
assess the repeatability five replicate measurements of each 
solution were made in a short period of time. To determine 
intermediate precision the solutions were each analysed five 
times per day for three consecutive days. 
The accuracy of the procedure was verified by perform- 
ing  recovery  assays  at  three  concentrations,  in     triplicate. 
In the evaluation of the SWAdSV method solutions of the 
pharmaceuticals containing 8.0 × 10−7 mol L−1 PRX were 
spiked with PRX standard to furnish final concentrations of 
1.1 × 10−6, 1.4 × 10−6, and 1.7 × 10−6 mol L−1 (i.e. additions 
of 3.0 × 10−7, 6.0 × 10−7, and 9.0 × 10−7 mol L−1). For  the 
flow-injection method spikes of 2.0 × 10−6, 4.0 × 10−6,  and 
6.0 × 10−6 mol L−1  were added to solutions of the    pharma- 
  
 
 
Fig. 2. Square-wave adsorptive-stripping voltammetry of a 5 × 10−7 mol L−1 PRX solution. Eacc = −1.0 V; f = 500 Hz; f:.Es =5 mV; f:.Ep = 25 mV. (I) Voltammograms 
for tacc = (1) 0, (2) 20, (3) 40, and (4) 60 s. (II) Effect of tacc on ip. 
 
ceuticals with a  PRX  concentration  of  5.0 × 10−6 mol L−1, 
to obtain final concentrations of 7.0 × 10−6, 9.0 × 10−6,  and 
1.1 × 10−5 mol L−1 PRX. 
2.3.3. Pharmaceutical analysis 
The adequacy of the developed methods was evaluated by 
quantifying PRX in several commercial pharmaceutical formu- 
lations available on the Portuguese market (labelled values of 
20 mg PRX tablet−1). For the analysis five tablets of each prod- 
uct were weighed, finely powdered, and a mass equivalent to 
about 10 mg of PRX was dissolved in 100.0 mL deionised water 
by sonication for 15 min. 
For batch analysis the resulting solution was diluted 55-fold 
with water and an adequate volume of this diluted solution was 
added to 10.00 mL of electrolyte contained in the  voltammet- 
ric cell. Standard additions between 0 and 1.10 × 10−6 mol L−1 
were made by adding increasing quantities of PRX standard to 
the sample solution contained in the voltammetric cell. This pro- 
cedure was repeated in triplicate for each pharmaceutical. There 
was no need for prior filtration of the sample because a large 
dilution was made and the standard addition method was used. 
Prior to the flow-injection technique the sample solution was 
filtered to prevent obstruction of the manifold tubing. Seven 
standards were prepared by placing 165-µ,L sample aliquots in 
10.00-mL volumetric flasks and standard additions between  0 
and 6.00 × 10−6 mol L−1  were made. The volume was   com- 
pleted with electrolyte and the solutions were injected into the 
FIA system. 
 
3. Results 
 
3.1. Analysis of paroxetine using SWAdSV 
 
The electrochemical activity of PRX, using SWV and 
SWAdSV, was only verified in the pH range from 5 to 9, in 
which the peak current intensity (ip) and peak potential (Ep) 
were independent of pH. Suitable sensitivity, repeatability, and 
peak definition were obtained using a pH 8.8 borate buffer. 
Because the highest ip was obtained by SWAdSV, this method 
was optimised for PRX analysis. For this purpose the accu- 
mulation potential (Eacc) was varied between −0.2 and −1.3 V 
using an accumulation time (tacc) of 30 s. The highest signal was 
obtained at an Eacc of −1.0 V, which was used in the subsequent 
studies. At this Eacc  the preconcentration of 5 × 10−7 mol L−1 
PRX at the electrode followed by a SWV scan resulted in a 
single stripping peak at approximately −1.55 V (Fig. 2I) which 
increased linearly with tacc for up to 60 s (Fig. 2II). For longer 
deposition times deviation of linearity was observed, indicat- 
ing that saturation coverage of the drop is gradually   achieved 
and that competitive adsorption may occur. Further optimisa- 
tion was carried out using a 5 × 10−7 mol L−1 PRX solution 
and a tacc of 30 s. To obtain maximum ip and repeatability the 
influence of the square-wave frequency (f, 100–2000 Hz), pulse 
step (f:.Es, 1–10 mV) and pulse amplitude (f:.Ep, 5–100 mV) on 
the stripping response were studied and optimised and led    to 
the following optimum conditions: f = 600 Hz, f:.Es =6 mV, and 
f:.Ep = 40 mV. 
Table 1 lists the achieved linear range, the LOD and LOQ val- 
ues obtained in the voltammetric determination of PRX, under 
the optimised conditions, for accumulation times of 10 and 30 s. 
Although longer accumulation times increase sensitivity they 
also lead to smaller linear ranges and lower sample-throughputs, 
so they were not included further in this study. 
Precision assays were carried out at three concentration levels 
for two accumulation times (10 and 30 s), the results obtained, 
expressed as the relative standard deviation (R.S.D.), ranged 
from 0.5% to 1.4% for repeatability and from 0.6% to 4.6% 
for intermediate precision (Table 2). These results indicate that 
the method is precise and also confirm the stability of the drug 
solutions during the evaluation period. 
 
 
Table 1 
Characteristics of the calibration curves of PRX obtained with SWAdSV 
 
 
tacc (s) Regression equation (−ip (A); CPRX (mol L−1)) n Linear range (mol L−1) Correlation coefficient LOD (mol L−1) LOQ (mol L−1) 
 
10 −ip = (1.13 ± 0.01)CPRX + (5.76 ± 1.88) × 10−8 14 3.00 × 10−7 to 2.90 × 10−6 0.9995 8.7 × 10−8 2.9 × 10−7 
30 −ip = (3.01 ± 0.05)CPRX + (3.57 ± 2.80) × 10−8 5 1.00 × 10−7 to 9.00 × 10−7 0.9984 6.2 × 10−8 2.1 × 10−7 
  
 
 
Fig. 3. Effect of dissolved oxygen on the voltammetric determination of PRX. PRX concentration: (1) 0; (2) 5 × 10−7; (3) 1 × 10−6 mol L−1. Eacc = –1.0 V; tacc = 30 s; 
f = 600 Hz; f:.Es =6 mV; f:.Ep = 40 mV. Deoxygenation time: (I) 300 s and (II) 0 s. 
 
Recovery assays were performed at three concentration lev- 
els (3.0 × 10−7, 6.0 × 10−7, and 9.0 × 10−7 mol L−1) and the 
results obtained, 98–102%, indicate that the method is    accu- 
rate and selective for PRX analysis in the used pharmaceutical 
products. 
Because of the high square-wave frequency (600 Hz) used the 
time-consuming deoxygenation of the analysed solution could 
be avoided. In Fig. 3 voltammograms with and without oxygen 
removal of different PRX solutions are shown. It can be   con- 
Table 3 
Determination of paroxetine in several drugs using SWAdSV    
Product CPRX  (mg tablet−1)a 
Seroxat (GlaxoSmithKline) 20.1 ± 0.1 
Paxetil (Bial) 20.4 ± 0.6 
Paroxetina Sandoz 20.3 ± 0.3 
Paroxetina Alpharma 20.0 ± 0.4 
PaxPar (Merck) 20.6 ± 0.2 
Paroxetina Merck gene´ricos 20.3 ± 0.1 
Paroxetina Generis 20.0 ± 0.3 
cluded that dissolved oxygen did not interfere significantly with    a  Mean ± S.D. (n = 3). 
the determination of PRX, enabling the inclusion of the HMDE 
in an FIA system, without prior or on-line oxygen removal, 
which leads to an increase in sample-throughput. 
 
3.2. Determination of paroxetine in pharmaceutical 
products using SWAdSV 
 
The method developed was applied in the determination of 
PRX in pharmaceutical products, using the procedure described 
previously. The results are reported in Table 3  and  are  in 
good  agreement  with  the  labelled  values  of  the    products 
 
 
nal because of the flow of electrolyte (borate buffer, pH 8.8) was 
observed. Dispersion of the injected sample was minimised by 
keeping the length of the tube between the injection valve and 
the HMDE as short as possible. 
A constant ip value was obtained for flow rates between 1.1 
and 1.7 mL min−1, which decreased for higher flow rates.    A 
flow rate of 1.5 mL min−1 provided suitable sample-throughput 
and sensitivity. Using this flow rate, an injection volume of 
500 µ,L, and a tube length of 50 cm between the injector   and 
(20 mg tablet−1). the detector, a constant concentration profile between ±18 and 
3.3. Determination of paroxetine using FIA-SWAdSV 
 
On the basis of the results obtained in the batch study, an 
SWAdSV flow-detection system for the analysis of PRX was 
used in a single-manifold FIA system. The adsorption and mea- 
surement steps were performed while the sample solution slug 
was flowing through the adapter head containing the mercury 
electrode. No significant perturbation of the voltammetric sig- 
 
Table 2 
Results from evaluation of the precision of SWAdSV 
 
 
Property tacc  (10 s) tacc  (30 s) 
 
 
1.4 (0.60) 1.3 (0.20) 
35 s after injection was obtained (Fig. 4). The length of this con- 
stant concentration zone can easily be controlled by changing the 
injection volume and the flow rate. The adsorption step and the 
voltammetric scan must be performed within this time interval. 
Repeatability (R.S.D.%) (n = 5) 
 
 
 
Intermediate precision (R.S.D.%) (n = 3) 
1.0 (1.5) 0.5 (0.50) 
0.5 (2.4) 0.6 (0.80) 
2.1 (0.60) 4.6 (0.20) 
0.6 (1.5) 0.9 (0.50) 
2.0 (2.4) 0.7 (0.80) 
   Fig. 4. Variation of ip  with time after sample injection for a 1 × 10−5 mol L−1 
Concentrations, in µ,mol L−1, are given in parentheses. PRX solution, tacc =3 s. 
  
Table 4 
Precision of the FIA-SWAdSV method 
Property 
 
Repeatability (R.S.D.%) (n = 5) 
 
 
 
Intermediate precision (R.S.D.%) (n = 3) 
Concentrations, in µ,mol L−1, are given in parentheses. 
 
 
 
 
 
2.4 (4.50) 
1.7 (9.00) 
2.3 (13.5) 
2.0 (4.50) 
0.4 (9.00) 
4.7 (13.5) 
The influence of the same parameters studied under batch 
conditions on ip, repeatability and sample-throughput were opti- 
mised using a 1 × 10−5 mol L−1  PRX solution. The optimum 
Eacc  was found to be −1.0 V,  according to the result  obtained 
in batch, and a linear variation of ip with tacc from 0 to 5 s 
was observed. For longer tacc (up to 10 s) no further increase 
of  ip  was  verified,  probably  because  of  saturation coverage 
of the drop, competitive adsorption, or removal of adsorbed 
species by the flow. For the optimisation of f (50–1000 Hz), f:.Es 
(1–10 mV), and f:.Ep (5–100 mV) a tacc of 3 s was applied and 
the optimum conditions for determination of PRX were estab- 
lished as f = 600 Hz, f:.Es =6 mV, and f:.Ep = 40 mV. Up to 120 
samples per hour could be analysed using the proposed flow 
system. 
Using   the   optimised   conditions   the   variation   of     ip 
with   CPRX    was   represented   by   a   straight-line  equation: 
−ip = (0.196 ± 0.003)CPRX − (1.05 ± 0.31) × 10−7 (r = 0.9995; 
n = 7), valid within the linear range 3.00 × 10−6  to 1.70 × 
10−5 mol L−1   PRX.  The  LOD  and  LOQ  were  found  to be 
4.8 × 10−7 and 1.6 × 10−6 mol L−1, respectively. Precision 
assays  were  carried  out  at  three  concentration  levels    and 
the results obtained, expressed as the relative standard devi- 
ation (R.S.D.), ranged from 1.7% to  2.4%  for repeatability 
and from 0.4% to 4.7% for intermediate precision (Table 4). 
These results indicate that the method is precise and also con- 
firm the stability of the drug solutions during the evaluation 
period. 
Recovery assays were performed at three concentration lev- 
els (2.0 × 10−6, 4.0 × 10−6, and 6.0 × 10−6 mol L−1) and the 
results obtained, 97–105%, indicate that the method is    accu- 
rate and selective for PRX analysis in the used pharmaceutical 
products. 
 
 
Table 5 
Determination of paroxetine in several drugs using FIA-SWAdSV 
 
 
Product CPRX  (mg tablet−1)a 
 
 
Seroxat (GlaxoSmithKline) 20.5 ± 0.5 
Paxetil (Bial) 19.8 ± 0.6 
Paroxetina Sandoz 20.2 ± 0.8 
Paroxetina Alpharma 20.2 ± 0.2 
PaxPar (Merck) 19.8 ± 0.6 
Paroxetina Merck gene´ricos 20.3 ± 0.4 
Paroxetina Generis 19.4 ± 0.2    
a  Mean ± S.D. (n = 3). 
 
 
Fig. 5. Flow-injection voltammograms obtained in the determination of PRX 
in Paroxetine Sandoz using the standard addition method. Standard additions 
of PRX (10−6 mol L−1): 0; 1.00; 2.00; 3.00; 4.01; 5.00; 6.00. Eacc = –1.0 V; 
tacc =3 s; f = 600 Hz; f:.Es =6 mV; f:.Ep = 40 mV; flow rate = 1.5 mL min−1. 
 
3.4. Determination of paroxetine in pharmaceutical 
products using FIA-SWAdSV 
 
The results obtained in the determination of PRX in pharma- 
ceutical products using FIA-SWAdSV can be seen in Table 5 and 
are in good agreement with the labelled values (20 mg tablet−1). 
Flow-injection voltammograms obtained in the quantification of 
PRX in Paroxetina Sandoz are shown in Fig. 5. 
 
4. Conclusions 
 
SWAdSV and FIA-SWAdSV analytical methods have been 
developed for the determination of paroxetine. This drug was 
quantified in pharmaceutical products and the results are in good 
agreement with the labelled values. The FIA method has the 
advantage of high sample throughput, significantly reducing the 
analysis time and costs. 
Further investigation is undertaken in order to determine PRX 
in biological samples using on-line sample extraction and using 
the HMDE flow cell in drug dissolution testing and as an HPLC 
detector. 
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